Psoriasis Treatment Market To Cross USD 56.16 Bn by 2032

Market Research Future (MRFR) has published a cooked research report on the “Global Psoriasis Treatment Market” that contains information from 2023 to 2032. The Global Psoriasis Treatment Market is estimated to register a CAGR of 7.8% during the forecast period of 2023 to 2032.

Market Highlights

Global Psoriasis Treatment Market is accounted to register a CAGR of 7.8% during the forecast period and is estimated to reach USD 56.16 Billion by 2032.

Psoriasis treatment refers to the medical interventions and therapies employed to manage the chronic autoimmune skin condition known as psoriasis. The goal of psoriasis treatment is to reduce inflammation, alleviate symptoms such as redness, itching, and scaling, and prevent flare-ups. Various treatment approaches are available, including topical treatments such as corticosteroids, vitamin D analogs, and retinoids applied directly to the affected skin areas. Systemic medications, such as oral or injectable drugs, may be prescribed for more severe cases. Additionally, phototherapy, involving controlled exposure to ultraviolet light, can also be an effective treatment option. The choice of treatment depends on the severity of the condition, patient preferences, and the recommendation of healthcare professionals, to improve the quality of life for individuals living with psoriasis.

Segment Analysis

The Global Psoriasis Treatment Market has been segmented based on Drug Class, and Treatment Type.

Based on Drug Class, the market is segmented into Tumor Necrosis Factor (TNF) Inhibitors {Adalimumab, Infliximab, Etanercept}, Anticholinergics {Ustekinumab, SecU.K.Inumab, Ixekizumab, Brodalumab}, Vitamin D Analogues {Calcitriol, Calcipotriol, Tacalcitol}. The Tumor Necrosis Factor (TNF) Inhibitors category dominates the Psoriasis Treatment market due to their high efficacy in reducing inflammation and controlling symptoms in moderate to severe cases of psoriasis.

Based on Treatment Type, the market is segmented into Topicals ({Over-The-Counter (OTC) Topicals, Topical Non-Steroids, Topical Steroids}, Systemic {Retinoid, Cyclosporine, Methotrexate}, Biologics {Tumor Necrosis Factor Alpha (TNF-Α) Inhibitors, InterleU.K.In 12 And 23 (IL-12/23) Inhibitors, Interle. The Topicals category dominates the Psoriasis Treatment market due to their widespread availability, ease of use, and effectiveness in managing mild to moderate symptoms of psoriasis.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of: Psoriasis Treatment Market Research Report

Key Players:

MRFR recognizes the following companies as the key players in the Global Psoriasis Treatment Market— Johnson & Johnson Services Inc, Pfizer Inc, LEO Pharma A/S, Novartis, Merck & Co Inc, UCB S.A., AbbVie Inc, Sun Pharmaceutical Industries Ltd, Eli Lilly and Company, Amgen Inc, Evelo Biosciences Inc.

Regional Analysis

The Global Psoriasis Treatment Market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Global Psoriasis Treatment Market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Global Psoriasis Treatment Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World's Global Psoriasis Treatment Market comprises of Middle East, Africa, and Latin America.

In 2021, North America emerged as the leading market for psoriasis treatment, benefiting from a large population affected by skin disorders, improved healthcare infrastructure, the introduction of advanced diagnostic technologies, favorable medical policies, and reimbursement schemes, all contributing to market growth.

The Europe Psoriasis Treatment market holds the second-largest market share, driven by the rising prevalence of psoriasis across European countries. This has generated a strong demand for therapeutic drugs, complemented by increased government initiatives in the region. Additionally, the growing number of start-ups focusing on psoriasis treatment has further propelled market growth.

The Asia-Pacific psoriasis treatment market is expected to witness significant growth during the forecast period. This can be attributed to increasing government efforts to raise awareness about the long-term consequences of psoriasis among the population. For instance, in January 2019, the Australian government included two new medicines (Ilumya and Tremfya) for psoriasis treatment in the Pharmaceutical Benefits Scheme (PBS), resulting in substantial cost savings of up to USD 32,600 per year for patients.

Key Findings of the Study

• North America held the largest market share in the psoriasis treatment market, driven by factors such as a high prevalence of skin disorders, advanced medical facilities, the introduction of new diagnostic technology, favorable medical policies, and reimbursement policies that contribute to market growth.


• Based on the Drug Class, the Market has been segmented into Tumor Necrosis Factor (TNF) Inhibitors holding the largest market in 2022.


• Johnson & Johnson Services Inc, Pfizer Inc, LEO Pharma A/S, Novartis, Merck & Co Inc, UCB S.A., AbbVie Inc, Sun Pharmaceutical Industries Ltd, Eli Lilly and Company, Amgen Inc, Evelo Biosciences Inc.